12:09 PM
 | 
Nov 08, 2018
 |  BC Extra  |  Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

Editor's Note: This article was updated on Nov 08, 2018 at 3:36 PM PST

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies for B cell-mediated autoimmune diseases.

Cabaletta's co-founders include Michael Milone, an associate professor of pathology at Penn and co-inventor of CAR T therapy Kymriah tisagenlecleucel from Novartis AG (NYSE:NVS;...

Read the full 243 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >